ID

16556

Description

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Keywords

Versions (4)
  1. 11/17/15 11/17/15 -
  2. 12/8/15 12/8/15 -
  3. 12/8/15 12/8/15 -
  4. 7/23/16 7/23/16 -
Uploaded on

July 23, 2016

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147

German English

Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40

1 forms  
Patient identification
Description

Patient identification

Alias
UMLS CUI-1
C1269815
Patient number?
Description

Patient Number

Data type

text

Alias
UMLS CUI [1]
C1830427
Date of consent
Description

Date of consent

Data type

date

Measurement units
  • dd/mm/yyyy
dd/mm/yyyy
Date of screening
Description

Date of screening

Data type

date

Measurement units
  • dd/mm/yyyy
Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C1710477
dd/mm/yyyy
Inclusion criteria
Description

Inclusion criteria

Alias
UMLS CUI-1
C1512693
Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type.
Description

Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type.

Data type

boolean

Alias
UMLS CUI [1]
C4027888
≥18 years (male and female)
Description

≥18 years (male and female)

Data type

boolean

Alias
UMLS CUI [1]
C0001779
Indications for treatment with adalimumab, ustekinumab or cyclosporine in accordance with the guidelines for psoriasis and the individual prescribing information.
Description

Indications for treatment with adalimumab, ustekinumab or cyclosporine in accordance with the guidelines for psoriasis and the individual prescribing information.

Data type

boolean

Alias
UMLS CUI [1]
C1122087
UMLS CUI [2]
C1608841
UMLS CUI [3]
C0010592
Patients with moderate to severe chronic plaque psoriasis who have not responded to other systemic therapy including cyclosporine, methotrexate or PUVA or who have a contraindication or intolerance to such therapy exists.
Description

Patients with moderate to severe chronic plaque psoriasis who have not responded to other systemic therapy including cyclosporine, methotrexate or PUVA or who have a contraindication or intolerance to such therapy exists.

Data type

integer

Alias
UMLS CUI [1,1]
C1524062
UMLS CUI [1,2]
C1512693
UMLS CUI [1,3]
C1122087
UMLS CUI [2,1]
C1524062
UMLS CUI [2,2]
C1512693
UMLS CUI [2,3]
C1608841
Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type, which are not sufficiently treated with conventional systemic therapy.
Description

Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type, which are not sufficiently treated with conventional systemic therapy.

Data type

integer

Alias
UMLS CUI [1,1]
C1524062
UMLS CUI [1,2]
C1512693
UMLS CUI [1,3]
C0010592
Exclusion criteria
Description

Exclusion criteria

Alias
UMLS CUI-1
C0680251
Therapy with systemic immunosuppressants (such as cyclosporine or methotrexate), adalimumab, etanercept, infliximab, or ustekinumab in a period of 5 half-lives of the respective medication before taking the initial swab specimens / biopsies.
Description

Therapy with systemic immunosuppressants (such as cyclosporine or methotrexate), adalimumab, etanercept, infliximab, or ustekinumab in a period of 5 half-lives of the respective medication before taking the initial swab specimens / biopsies.

Data type

boolean

Alias
UMLS CUI [1,1]
C0021079
UMLS CUI [1,2]
C0205373
Concurrent therapy with systemic immunosuppressants.
Description

Concurrent therapy with systemic immunosuppressants.

Data type

boolean

Alias
UMLS CUI [1,1]
C0009429
UMLS CUI [1,2]
C0021079
UMLS CUI [1,3]
C0205373
Antibiotic therapy over a period of at least 4 weeks before taking the initial swab specimens / biopsies or antibiotic therapy during the study.
Description

Antibiotic therapy over a period of at least 4 weeks before taking the initial swab specimens / biopsies or antibiotic therapy during the study.

Data type

boolean

Alias
UMLS CUI [1]
C0338237
Psoriasis patients who currently receive or have received phototherapy for a period of 2 weeks before the withdrawal of the initial swab specimens / biopsies.
Description

Psoriasis patients who currently receive or have received phototherapy for a period of 2 weeks before the withdrawal of the initial swab specimens / biopsies.

Data type

boolean

Alias
UMLS CUI [1]
C0031765
Patients who can not interrupt the local, topical therapy with calcineurin inhibitors or vitamin D3 analogues in the conditions laid down for the smear preparations / biopsies skin areas. The topical treatment with calcineurin inhibitors or vitamin D3 analogs can be continued in lesional skin areas that are not intended for smear preparations / biopsies. In the conditions laid down for the smear preparations / biopsies skin areas must be done 7 days prior to taking the samples no topical therapy.
Description

Patients who can not interrupt the local, topical therapy with calcineurin inhibitors or vitamin D3 analogues in the conditions laid down for the smear preparations / biopsies skin areas. The topical treatment with calcineurin inhibitors or vitamin D3 analogs can be continued in lesional skin areas that are not intended for smear preparations / biopsies. In the conditions laid down for the smear preparations / biopsies skin areas must be done 7 days prior to taking the samples no topical therapy.

Data type

boolean

Alias
UMLS CUI [1]
C3888969
Clinically significant active infection (eg active tuberculosis or other severe infections such as sepsis and opportunistic infections). Latent tuberculosis. A history of latent or active tuberculosis that has not been adequately treated safely.
Description

Clinically significant active infection (eg active tuberculosis or other severe infections such as sepsis and opportunistic infections). Latent tuberculosis. A history of latent or active tuberculosis that has not been adequately treated safely.

Data type

boolean

Alias
UMLS CUI [1]
C0009450
Chronic carriers of the hepatitis B virus (HBsAg positive).
Description

Chronic carriers of the hepatitis B virus (HBsAg positive).

Data type

boolean

Alias
UMLS CUI [1]
C0149709
HIV-positive patients
Description

HIV-positive patients.

Data type

boolean

Alias
UMLS CUI [1]
C0019699
Maligne Erkrankungen aktuell oder in der Vorgeschichte.
Description

Malignancies current or history.

Data type

boolean

Alias
UMLS CUI [1]
C0006826
Immunodeficient patients (primary disease or as a result of therapy)
Description

Immunodeficient patients (primary disease or as a result of therapy).

Data type

boolean

Alias
UMLS CUI [1]
C0021051
Patients receiving chemotherapy or radiation therapy or currently one who received chemotherapy / radiotherapy within the last 12 months before the withdrawal of the initial swab specimens / biopsies.
Description

Patients receiving chemotherapy or radiation therapy or currently one who received chemotherapy / radiotherapy within the last 12 months before the withdrawal of the initial swab specimens / biopsies.

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
Patients are not stable with uncontrolled chronic diseases that require continuous treatment (such as diabetes, hepatitis, organ transplantation), and from the perspective of the investigator.
Description

Patients are not stable with uncontrolled chronic diseases that require continuous treatment (such as diabetes, hepatitis, organ transplantation), and from the perspective of the investigator.

Data type

boolean

Alias
UMLS CUI [1,1]
C0008679
UMLS CUI [1,2]
C0205318
Patients with other chronic skin diseases such as atopic dermatitis or lupus erythematosus that may affect the cutaneous microbiota.
Description

Patients with other chronic skin diseases such as atopic dermatitis or lupus erythematosus that may affect the cutaneous microbiota.

Data type

boolean

Alias
UMLS CUI [1]
C1290009
Patients with psychiatric comorbidity, which cause a lack or lack of capacity to consent.
Description

Patients with psychiatric comorbidity, which cause a lack or lack of capacity to consent.

Data type

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0009488
Participation in another interventional examination before study completion in a period of 4 weeks and 5 half-lives of the former investigational, whichever is longer.
Description

Participation in another interventional examination before study completion in a period of 4 weeks and 5 half-lives of the former investigational, whichever is longer.

Data type

boolean

Alias
UMLS CUI [1]
C2348568
For childbearing women or men with female partners of childbearing unwillingness reliable forms of contraception (Pearl index <1) apply. With Stelara® patients treated these contraceptive methods have to at least 15 weeks after the end of treatment with Humira® patients treated for at least 5 months after the end of treatment continue.
Description

For childbearing women or men with female partners of childbearing unwillingness reliable forms of contraception (Pearl index <1) apply. With Stelara® patients treated these contraceptive methods have to at least 15 weeks after the end of treatment with Humira® patients treated for at least 5 months after the end of treatment continue.

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Patients who were positive for MRSA in the history over a period of 6 months prior to withdrawal of the first swab specimens / biopsies.
Description

Patients who were positive for MRSA in the history over a period of 6 months prior to withdrawal of the first swab specimens / biopsies.

Data type

boolean

Alias
UMLS CUI [1]
C0343401
Patients with psoriasis vulgaris exclusively in the head area.
Description

Patients with psoriasis vulgaris exclusively in the head area.

Data type

boolean

Alias
UMLS CUI [1,1]
C0263361
UMLS CUI [1,2]
C0018670
Additional exclusion criteria Adalimumab
Description

Additional exclusion criteria Adalimumab

Alias
UMLS CUI-1
C0680251
UMLS CUI-2
C1122087
Hypersensitivity to the active substance or to any of the excipients of Humira®.
Description

Hypersensitivity to the active substance or to any of the excipients of Humira®.

Data type

integer

Alias
UMLS CUI [1]
C0020517
Moderate to severe heart failure (NYHA class III / IV).
Description

Moderate to severe heart failure (NYHA class III / IV).

Data type

integer

Alias
UMLS CUI [1]
C1275491
Pre-existing or incipient demyelinating diseases of the CNS or peripheral nervous system.
Description

Pre-existing or incipient demyelinating diseases of the CNS or peripheral nervous system.

Data type

integer

Alias
UMLS CUI [1]
C0751873
Concurrent therapy with anakinra or abatacept.
Description

Concurrent therapy with anakinra or abatacept.

Data type

integer

Alias
UMLS CUI [1]
C0245109
UMLS CUI [2]
C1619966
Concomitant vaccination with live vaccines. This applies for a period up to 5 months after end of therapy.
Description

Concomitant vaccination with live vaccines. This applies for a period up to 5 months after end of therapy.

Data type

integer

Alias
UMLS CUI [1]
C0042196
Additional exclusion criteria Ustekinumab
Description

Additional exclusion criteria Ustekinumab

Alias
UMLS CUI-1
C0680251
UMLS CUI-2
C1608841
Hypersensitivity to the active substance or to any of the excipients of Stelara®, allergy to latex.
Description

Hypersensitivity to the active substance or to any of the excipients of Stelara®, allergy to latex.

Data type

integer

Alias
UMLS CUI [1]
C0020517
Simultaneous vaccination with live viruses or live bacteria. This applies for a period of 2 weeks prior to initiation of therapy with Stelara® until at least 15 weeks after end of therapy.
Description

Simultaneous vaccination with live viruses or live bacteria. This applies for a period of 2 weeks prior to initiation of therapy with Stelara® until at least 15 weeks after end of therapy.

Data type

integer

Alias
UMLS CUI [1]
C0042196
Additional exclusion criteria Cyclosporine
Description

Additional exclusion criteria Cyclosporine

Alias
UMLS CUI-1
C0680251
UMLS CUI-2
C0010592
Known hypersensitivity to ciclosporin and / or against any of the excipients of the ciclosporin preparation.
Description

Known hypersensitivity to ciclosporin and / or against any of the excipients of the ciclosporin preparation.

Data type

integer

Alias
UMLS CUI [1]
C0020517
Uncontrolled arterial hypertension.
Description

Uncontrolled arterial hypertension.

Data type

integer

Alias
UMLS CUI [1]
C1868885
Uncontrolled infectious diseases.
Description

Uncontrolled infectious diseases.

Data type

integer

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205318
Not healed infection with varicella, incl. Herpes zoster infection, herpes simplex infections, and other viral infections (eg, mollusks, condyloma, multiple warts)
Description

Not healed infection with varicella, incl. Herpes zoster infection, herpes simplex infections, and other viral infections (eg, mollusks, condyloma, multiple warts)

Data type

integer

Alias
UMLS CUI [1]
C0586989
Relevant renal impairment
Description

Relevant renal impairment

Data type

integer

Alias
UMLS CUI [1]
C1565489
Severe liver disease, GOT> 2 x ULN, GPT> 2x ULN, yGT> 2 x ULN, bilirubin> 2 x ULN
Description

Severe liver disease, GOT> 2 x ULN, GPT> 2x ULN, yGT> 2 x ULN, bilirubin> 2 x ULN

Data type

integer

Alias
UMLS CUI [1]
C3829821
Hyperuricemia
Description

Hyperuricemia

Data type

integer

Alias
UMLS CUI [1]
C0740394
Hyperkalemia
Description

Hyperkalemia

Data type

integer

Alias
UMLS CUI [1]
C0020461
State after prior PUVA therapy with cumulative dose> 1000 J / cm²
Description

State after prior PUVA therapy with cumulative dose> 1000 J / cm²

Data type

integer

Alias
UMLS CUI [1]
C0853073
State after many years of methotrexate therapy
Description

State after many years of methotrexate therapy

Data type

integer

Alias
UMLS CUI [1]
C0025677
Therapy with Etretinate within 4 weeks prior to initiating therapy with cyclosporine
Description

Therapy with Etretinate within 4 weeks prior to initiating therapy with cyclosporine

Data type

integer

Alias
UMLS CUI [1]
C0015137
Concurrent therapy with retinoids
Description

Concurrent therapy with retinoids

Data type

integer

Alias
UMLS CUI [1]
C3653550
Concurrent therapy with coal tar
Description

Concurrent therapy with coal tar

Data type

integer

Alias
UMLS CUI [1]
C0009137
Concurrent therapy with simvastatin
Description

Concurrent therapy with simvastatin

Data type

integer

Alias
UMLS CUI [1]
C0074554
Concurrent therapy with tacrolimus
Description

Concurrent therapy with tacrolimus

Data type

integer

Alias
UMLS CUI [1]
C0085149
Concomitant use of St. John's wort (Hypericum perforatum)
Description

Concomitant use of St. John's wort (Hypericum perforatum)

Data type

integer

Alias
UMLS CUI [1]
C0936242
Concomitant therapy with drugs that are substrates of multidrug efflux transporters P-glycoprotein or Organic Anion Transporting Polypeptides and are joined for the increased plasma concentrations with serious and / or life-threatening events, such as Bosentan, Dabigatran-Etexilate and Aliskiren.
Description

Concomitant therapy with drugs that are substrates of multidrug efflux transporters P-glycoprotein or Organic Anion Transporting Polypeptides and are joined for the increased plasma concentrations with serious and / or life-threatening events, such as Bosentan, Dabigatran-Etexilate and Aliskiren.

Data type

integer

Alias
UMLS CUI [1]
C0069906
UMLS CUI [2]
C0949791
Concomitant vaccination with live vaccines
Description

Concomitant vaccination with live vaccines

Data type

integer

Alias
UMLS CUI [1]
C0042196
Alcohol disease, contraindication to the use of alcohol (eg. epilepsy)
Description

Alcohol disease, contraindication to the use of alcohol (eg. epilepsy)

Data type

integer

Alias
UMLS CUI [1]
C0038586
Erythrodermic or pustular psoriasis
Description

Erythrodermic or pustular psoriasis

Data type

integer

Alias
UMLS CUI [1]
C0748052
UMLS CUI [2]
C0152081
Psoriatic forms that may be caused or exacerbated by drugs.
Description

Psoriatic forms that may be caused or exacerbated by drugs.

Data type

integer

Alias
UMLS CUI [1]
C1304130
Back to the top of the page

Similar models

Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Patient identification
C1269815 (UMLS CUI-1)
Patient number
Item
Patient number?
text
C1830427 (UMLS CUI [1])
Date of consent
Item
Date of consent
date
Date of screening
Item
Date of screening
date
C0011008 (UMLS CUI [1,1])
C1710477 (UMLS CUI [1,2])
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
PASI
Item
Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type.
boolean
C4027888 (UMLS CUI [1])
Age
Item
≥18 years (male and female)
boolean
C0001779 (UMLS CUI [1])
Adalimumab, ustekinumab or cyclosporine
Item
Indications for treatment with adalimumab, ustekinumab or cyclosporine in accordance with the guidelines for psoriasis and the individual prescribing information.
boolean
C1122087 (UMLS CUI [1])
C1608841 (UMLS CUI [2])
C0010592 (UMLS CUI [3])
Item
Patients with moderate to severe chronic plaque psoriasis who have not responded to other systemic therapy including cyclosporine, methotrexate or PUVA or who have a contraindication or intolerance to such therapy exists.
integer
C1524062 (UMLS CUI [1,1])
C1512693 (UMLS CUI [1,2])
C1122087 (UMLS CUI [1,3])
C1524062 (UMLS CUI [2,1])
C1512693 (UMLS CUI [2,2])
C1608841 (UMLS CUI [2,3])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Patients with moderate to severe chronic plaque psoriasis who have not responded to other systemic therapy including cyclosporine, methotrexate or PUVA or who have a contraindication or intolerance to such therapy exists.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type, which are not sufficiently treated with conventional systemic therapy.
integer
C1524062 (UMLS CUI [1,1])
C1512693 (UMLS CUI [1,2])
C0010592 (UMLS CUI [1,3])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type, which are not sufficiently treated with conventional systemic therapy.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
Systemic immunosuppressants
Item
Therapy with systemic immunosuppressants (such as cyclosporine or methotrexate), adalimumab, etanercept, infliximab, or ustekinumab in a period of 5 half-lives of the respective medication before taking the initial swab specimens / biopsies.
boolean
C0021079 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Concurrent therapy with systemic immunosuppressants
Item
Concurrent therapy with systemic immunosuppressants.
boolean
C0009429 (UMLS CUI [1,1])
C0021079 (UMLS CUI [1,2])
C0205373 (UMLS CUI [1,3])
Antibiotic therapy
Item
Antibiotic therapy over a period of at least 4 weeks before taking the initial swab specimens / biopsies or antibiotic therapy during the study.
boolean
C0338237 (UMLS CUI [1])
Phototherapy
Item
Psoriasis patients who currently receive or have received phototherapy for a period of 2 weeks before the withdrawal of the initial swab specimens / biopsies.
boolean
C0031765 (UMLS CUI [1])
Temporary interruption of therapy
Item
Patients who can not interrupt the local, topical therapy with calcineurin inhibitors or vitamin D3 analogues in the conditions laid down for the smear preparations / biopsies skin areas. The topical treatment with calcineurin inhibitors or vitamin D3 analogs can be continued in lesional skin areas that are not intended for smear preparations / biopsies. In the conditions laid down for the smear preparations / biopsies skin areas must be done 7 days prior to taking the samples no topical therapy.
boolean
C3888969 (UMLS CUI [1])
Infection
Item
Clinically significant active infection (eg active tuberculosis or other severe infections such as sepsis and opportunistic infections). Latent tuberculosis. A history of latent or active tuberculosis that has not been adequately treated safely.
boolean
C0009450 (UMLS CUI [1])
HBsAg positive
Item
Chronic carriers of the hepatitis B virus (HBsAg positive).
boolean
C0149709 (UMLS CUI [1])
HIV-positive
Item
HIV-positive patients
boolean
C0019699 (UMLS CUI [1])
Malignancies
Item
Maligne Erkrankungen aktuell oder in der Vorgeschichte.
boolean
C0006826 (UMLS CUI [1])
Immunodeficient patients
Item
Immunodeficient patients (primary disease or as a result of therapy)
boolean
C0021051 (UMLS CUI [1])
Chemotherapy or radiation therapy
Item
Patients receiving chemotherapy or radiation therapy or currently one who received chemotherapy / radiotherapy within the last 12 months before the withdrawal of the initial swab specimens / biopsies.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
Uncontrolled chronic diseases
Item
Patients are not stable with uncontrolled chronic diseases that require continuous treatment (such as diabetes, hepatitis, organ transplantation), and from the perspective of the investigator.
boolean
C0008679 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Chronic skin diseases
Item
Patients with other chronic skin diseases such as atopic dermatitis or lupus erythematosus that may affect the cutaneous microbiota.
boolean
C1290009 (UMLS CUI [1])
Psychiatric comorbidity
Item
Patients with psychiatric comorbidity, which cause a lack or lack of capacity to consent.
boolean
C0004936 (UMLS CUI [1,1])
C0009488 (UMLS CUI [1,2])
Study participation status
Item
Participation in another interventional examination before study completion in a period of 4 weeks and 5 half-lives of the former investigational, whichever is longer.
boolean
C2348568 (UMLS CUI [1])
Pregnancy or lactation
Item
For childbearing women or men with female partners of childbearing unwillingness reliable forms of contraception (Pearl index <1) apply. With Stelara® patients treated these contraceptive methods have to at least 15 weeks after the end of treatment with Humira® patients treated for at least 5 months after the end of treatment continue.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
MRSA
Item
Patients who were positive for MRSA in the history over a period of 6 months prior to withdrawal of the first swab specimens / biopsies.
boolean
C0343401 (UMLS CUI [1])
Psoriasis vulgaris: head area
Item
Patients with psoriasis vulgaris exclusively in the head area.
boolean
C0263361 (UMLS CUI [1,1])
C0018670 (UMLS CUI [1,2])
Item Group
Additional exclusion criteria Adalimumab
C0680251 (UMLS CUI-1)
C1122087 (UMLS CUI-2)
Item
Hypersensitivity to the active substance or to any of the excipients of Humira®.
integer
C0020517 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hypersensitivity to the active substance or to any of the excipients of Humira®.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Moderate to severe heart failure (NYHA class III / IV).
integer
C1275491 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Moderate to severe heart failure (NYHA class III / IV).
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Pre-existing or incipient demyelinating diseases of the CNS or peripheral nervous system.
integer
C0751873 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Pre-existing or incipient demyelinating diseases of the CNS or peripheral nervous system.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concurrent therapy with anakinra or abatacept.
integer
C0245109 (UMLS CUI [1])
C1619966 (UMLS CUI [2])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with anakinra or abatacept.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concomitant vaccination with live vaccines. This applies for a period up to 5 months after end of therapy.
integer
C0042196 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant vaccination with live vaccines. This applies for a period up to 5 months after end of therapy.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item Group
Additional exclusion criteria Ustekinumab
C0680251 (UMLS CUI-1)
C1608841 (UMLS CUI-2)
Item
Hypersensitivity to the active substance or to any of the excipients of Stelara®, allergy to latex.
integer
C0020517 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hypersensitivity to the active substance or to any of the excipients of Stelara®, allergy to latex.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Simultaneous vaccination with live viruses or live bacteria. This applies for a period of 2 weeks prior to initiation of therapy with Stelara® until at least 15 weeks after end of therapy.
integer
C0042196 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Simultaneous vaccination with live viruses or live bacteria. This applies for a period of 2 weeks prior to initiation of therapy with Stelara® until at least 15 weeks after end of therapy.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item Group
Additional exclusion criteria Cyclosporine
C0680251 (UMLS CUI-1)
C0010592 (UMLS CUI-2)
Item
Known hypersensitivity to ciclosporin and / or against any of the excipients of the ciclosporin preparation.
integer
C0020517 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Known hypersensitivity to ciclosporin and / or against any of the excipients of the ciclosporin preparation.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Uncontrolled arterial hypertension.
integer
C1868885 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Uncontrolled arterial hypertension.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Uncontrolled infectious diseases.
integer
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Uncontrolled infectious diseases.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Not healed infection with varicella, incl. Herpes zoster infection, herpes simplex infections, and other viral infections (eg, mollusks, condyloma, multiple warts)
integer
C0586989 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Not healed infection with varicella, incl. Herpes zoster infection, herpes simplex infections, and other viral infections (eg, mollusks, condyloma, multiple warts)
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Relevant renal impairment
integer
C1565489 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Relevant renal impairment
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Severe liver disease, GOT> 2 x ULN, GPT> 2x ULN, yGT> 2 x ULN, bilirubin> 2 x ULN
integer
C3829821 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Severe liver disease, GOT> 2 x ULN, GPT> 2x ULN, yGT> 2 x ULN, bilirubin> 2 x ULN
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Hyperuricemia
integer
C0740394 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hyperuricemia
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Hyperkalemia
integer
C0020461 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hyperkalemia
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
State after prior PUVA therapy with cumulative dose> 1000 J / cm²
integer
C0853073 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
State after prior PUVA therapy with cumulative dose> 1000 J / cm²
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
State after many years of methotrexate therapy
integer
C0025677 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
State after many years of methotrexate therapy
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Therapy with Etretinate within 4 weeks prior to initiating therapy with cyclosporine
integer
C0015137 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Therapy with Etretinate within 4 weeks prior to initiating therapy with cyclosporine
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concurrent therapy with retinoids
integer
C3653550 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with retinoids
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concurrent therapy with coal tar
integer
C0009137 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with coal tar
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concurrent therapy with simvastatin
integer
C0074554 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with simvastatin
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concurrent therapy with tacrolimus
integer
C0085149 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with tacrolimus
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concomitant use of St. John's wort (Hypericum perforatum)
integer
C0936242 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant use of St. John's wort (Hypericum perforatum)
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concomitant therapy with drugs that are substrates of multidrug efflux transporters P-glycoprotein or Organic Anion Transporting Polypeptides and are joined for the increased plasma concentrations with serious and / or life-threatening events, such as Bosentan, Dabigatran-Etexilate and Aliskiren.
integer
C0069906 (UMLS CUI [1])
C0949791 (UMLS CUI [2])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant therapy with drugs that are substrates of multidrug efflux transporters P-glycoprotein or Organic Anion Transporting Polypeptides and are joined for the increased plasma concentrations with serious and / or life-threatening events, such as Bosentan, Dabigatran-Etexilate and Aliskiren.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Concomitant vaccination with live vaccines
integer
C0042196 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant vaccination with live vaccines
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Alcohol disease, contraindication to the use of alcohol (eg. epilepsy)
integer
C0038586 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Alcohol disease, contraindication to the use of alcohol (eg. epilepsy)
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Erythrodermic or pustular psoriasis
integer
C0748052 (UMLS CUI [1])
C0152081 (UMLS CUI [2])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Erythrodermic or pustular psoriasis
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Psoriatic forms that may be caused or exacerbated by drugs.
integer
C1304130 (UMLS CUI [1])
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Psoriatic forms that may be caused or exacerbated by drugs.
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial